Comment from American Urological Association (AUA)
AnonymousSupportAdvocacy
Summary: The American Urological Association (AUA) supports the proposed pilot program to assess AI-enabled technologies in early-phase clinical trials, highlighting its potential to improve recruitment, safety monitoring, and decision-making. They provide specific recommendations on pilot design, participant selection, and evaluation metrics, emphasizing the need for human oversight, transparency, and broad representation across therapeutic areas.
The American Urological Association (AUA) appreciates the opportunity to provide input on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trials. Please see attached file for our comments.